Premium
The insulin‐like growth factor‐I/binding protein axis: physiology, pathophysiology and therapeutic manipulation
Author(s) -
LANGFORD K. S.,
MIELL J. P.
Publication year - 1993
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1993.tb00958.x
Subject(s) - paracrine signalling , autocrine signalling , growth factor , insulin like growth factor , endocrine system , insulin , biology , pathophysiology , insulin like growth factor binding protein , microbiology and biotechnology , endocrinology , hormone , receptor , biochemistry
. Insulin‐like growth factor‐I (IGF‐I) is a single‐chain polypeptide which has multiple metabolic actions and effects on the differentiation and proliferation of a wide variety of cell types. IGF‐I has endocrine, paracrine and autocrine actions and is bound in the circulation to a complex system of binding proteins which alter its bioavailability and activity. Thus its physiology is complex and is altered in a number of pathological states. This review will discuss these states and the actual and proposed therapeutic applications of recombinant human IGF‐I (rhIGF‐I).